Who are Tri-Luma's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trusopt, Ammonul, Lithostat, Zinacef, Cinobac, Dihydrex.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hydroquinone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tri-Luma — Competitive Intelligence Brief

Tri-Luma (HYDROQUINONE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Melanin Synthesis Inhibitor [EPC]. Area: Pain.

marketed Melanin Synthesis Inhibitor [EPC] Carbonic anhydrase 2 Pain Small molecule Live · refreshed every 30 min

Target snapshot

Tri-Luma (HYDROQUINONE) — Galderma Labs Lp.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tri-Luma TARGET	HYDROQUINONE	Galderma Labs Lp	marketed	Melanin Synthesis Inhibitor [EPC]	Carbonic anhydrase 2	2002-01-01
Trusopt	DORZOLAMIDE	Merck & Co.	marketed	Carbonic Anhydrase Inhibitor	Carbonic anhydrase 2	1994-01-01
Ammonul	SODIUM BENZOATE		marketed	sodium benzoate	Carbonic anhydrase 2	1987-01-01
Lithostat	ACETOHYDROXAMIC ACID	Mission Pharma	marketed	Urease Inhibitor [EPC]	Carbonic anhydrase 2	1983-01-01
Zinacef	CEFUROXIME	GSK	marketed	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Cinobac	CINOXACIN	Eli Lilly	marketed	cinoxacin	Carbonic anhydrase 2	1980-01-01
Dihydrex	BENZTHIAZIDE	Ah Robins Inc	marketed	benzthiazide	Calcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2	1960-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Melanin Synthesis Inhibitor [EPC] class)

Galderma Labs Lp · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tri-Luma — Competitive Intelligence Brief. https://druglandscape.com/ci/hydroquinone. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab